A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Asthmatic Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist (CALIMA)

Trial Profile

A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Asthmatic Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist (CALIMA)

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Benralizumab (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms CALIMA
  • Sponsors AstraZeneca
  • Most Recent Events

    • 11 Sep 2017 Post-hoc results of SIROCCO and CALIMA trials results were presented at the European Respiratory Society (ERS) International Congress 2017 and were published simultaneously today in The Lancet Respiratory Medicine, according to an AstraZeneca media release.
    • 11 Sep 2017 Post-hoc results of SIROCCO and CALIMA trials published in an AstraZeneca media release.
    • 24 May 2017 Results of a pooled analysis assessing patient-reported outcomes in Asthma patients from two phase III trials (NCT01928771 and NCT01914757; n=1530), presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top